These independent CME/CE activities are supported by educational grants from

AbbVie Inc.

Certificate Program Banner Goes Here
  1. Course List
faculty image
Bruce D. Cheson, MD, FACP, FAAAS
  • Professor of Medicine
  • Head of Hematology and Deputy Chief
  • Division of Hematology-Oncology
  • Georgetown University Hospital
  • Lombardi Comprehensive Cancer Center
  • Washington, DC
  • Master Class: Chronic Lymphocytic Leukemia (CLL) is designed to highlight relevant, practical advances in the treatment of CLL using a modular structure to provide an in-depth review of best practices with multiple complementary activities, including video webcasts with expert clinical specialists, case studies utilizing current and emerging therapies based on the most up-to-date evidence-based medicine, and review of articles from peer-reviewed scientific journals. Modules cover the role of minimal residual disease in guiding treatment decisions for patients on targeted therapies, such as ibrutinib and venetoclax, and treatment considerations for patients with ibrutinib-refractory CLL, including the role of venetoclax and emerging agents in this difficult-to-treat population.
  • Summarize the rationale for using minimal residual disease (MRD) as an endpoint and strategies for achieving MRD negativity
  • Implement personalized treatment strategies for patients with ibrutinib-refractory CLL using patient factors to guide selection
  • Describe supportive care, prophylaxis of TLS, and special considerations for the use of small-molecule inhibitors in the treatment of CLL
  • Target Audience

    The target audience for this activity series includes the care team that manages patients with chronic lymphocytic leukemia, including hematologists, oncologists, primary care physicians, nurse practitioners, physician assistants, nurses, and pharmacists.


    Activity Goal

    The goal of this program is to enhance the contemporary management of chronic lymphocytic leukemia and patient outcomes. Focusing on evolving concepts and addressing clinical challenges, the Master Class curriculum will include innovative webcasts derived from the latest evidence, interactive real-world cases, and faculty insights from recent peer-reviewed journal articles. The program is designed to provide scientific and practical knowledge that can be applied by practicing clinicians directly into their clinical practice.